Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal CancerScott Kopetz, Josep Tabernero, Tae-Won Kim et al.|New England Journal of Medicine|2019Cited by 1.5k
Treatment of Metastatic Colorectal Cancer: ASCO GuidelineVan K. Morris, Cathy Eng|Journal of Clinical Oncology|2022Cited by 580
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Howard S. Höchster, Katherine A. Guthrie et al.|Journal of Clinical Oncology|2020Cited by 391
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaperArvind Dasari, Scott Kopetz, Van K. Morris et al.|Nature Reviews Clinical Oncology|2020Cited by 365
Clinical and molecular characterization of early‐onset colorectal cancerAlexandra N. Willauer, Jonathan M. Loree, Yusha Liu et al.|Cancer|2019Cited by 361